For Immediate Release
February 10, 2021
Contact: Steven Grossman (301-257-9660)

In response to media inquiries, the Alliance for a Stronger FDA has issued the following statement:

The FDA stakeholder community appreciates and supports the House Energy and Commerce Committee’s decision to include $500 million in no-year money to support COVID-19 activities at FDA. This assures that FDA has the funds it needs as its workload grows and shifts in response to the pandemic. Neither the pandemic nor FDA responsibilities in this area can be neatly segmented by fiscal year, so the flexibility provided by these funds is enormously valuable.

Apart from its COVID-19 work, FDA’s mission and responsibilities have grown considerably in the last year and additional base funding will be needed in FY 22. We look forward to working with the Administration and the Appropriations committees to fully support the agency’s funding needs in areas such as food safety, cell and gene therapy, digital health, and advanced manufacturing.